<PAGE>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                               FORM 10-QSB/A No. 1

[xx] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
     ACT OF 1934

For the quarterly period ended September 30, 1996
                               ------------------
                                       or

[ ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

For the transition period from                 to               
                               ---------------    --------------

Commission File Number:            33-14042-NY
                        -----------------------------------

                  NeuroCorp. (formerly Tamarac Ventures, Ltd.)
-------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

          Nevada                                            87-0446395
--------------------------------                  -----------------------------
(State or other jurisdiction of                          (I.R.S. Employer
incorporation or organization)                         Identification No.)

150 White Plains Road, Tarrytown, New York                            10591
-------------------------------------------------------------------------------
(Address of principal executive offices)                            (Zip Code)

                                 (914) 631-3315
-------------------------------------------------------------------------------
              (Registrant's telephone number, including area code)


-------------------------------------------------------------------------------
              (Former name, former address and former fiscal year,
                          if changed since last report)

Check whether the issuer (1) has filed all reports required to be filed by
section 13 or 15 (d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
                                                               Yes [xx]  No [  ]
           APPLICABLE ONLY TO CORPORATE ISSUERS INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant filed all documents and reports required to be
filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of
securities under a plan confirmed by a court.
                                                               Yes [  ]  No [  ]
                      APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common
equity as of the latest practicable date:  7,173,807 Shares as of September 30,
1996.

<PAGE>



                                  FORM 10-QSB

                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the 
Registrant has duly caused this report to be signed on its behalf by the 
undersigned thereunto duly authorized.


                                          NeuroCorp. Ltd.
                                       -----------------------------------
                                           (Registrant)

November 20, 1996                         /s/ Turan M. Itil, M.D.
-----------------                      -----------------------------------
     Date                                 By: Turan M. Itil, M.D.
                                          Chief Executive Officer and
                                          Director


<PAGE>


                              FORM 10-QSB/A No. 1

                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the 
Registrant has duly caused this report to be signed on its behalf by the 
undersigned thereunto duly authorized.


                                          NeuroCorp. Ltd.
                                       -----------------------------------
                                           (Registrant)

December 23, 1996                         /s/ Turan M. Itil, M.D.
-----------------                      -----------------------------------
     Date                                 By: Turan M. Itil, M.D.
                                          Chief Executive Officer and
                                          Director





<PAGE>

                     OPTON HANDLER GOTTLIEB FEILER & KATZ
                        
                             52 VANDERBILT AVENUE
                            NEW YORK, NEW YORK 10017
                            TELEPHONE (212) 599-1744
                            TELEPHONE (212) 972-2219


                             DECEMBER 23, 1996



Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549


       Re:  NEUROCORP, LTD.
            FILE NO. 33-14042-144


Dear Ladies and Gentlemen:

           Enclosed please find Amendment No. 1 to Form 10-QSB for the 
quarterly period ended September 30, 1996. This Amendment relates only to the 
Signature Page of the Form 10-QSB which was inadvertently omitted from the 
original filing.


                                  Very truly yours,



                                  Peter Landau


PL: mdy
Enclosure